EGFR and neoplasm: Although more and more studies have confirmed the superior efficacy of Osimertinib in NSCLC paitents with EGFR driver mutations 5, 12, 20-22, the tumor response and survival outcomes after the treatment of Osimertinib are usually different in patients.